2023-05-01 04:28:53 ET
- MediciNova ( NASDAQ: MNOV ) said it received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering MN-001 (tipelukast) to treat advanced nonalcoholic steatohepatitis (NASH), a type of liver disease.
- The patent, when issued, is expected to expire no earlier than May 2035.
- The company added that the allowed claims also cover the treatment of patients with advanced NASH which show hepatic fibrosis, spider angiomata, ascites, splenomegaly, hard liver border, palmar erythema, asterixis, portal hypertension, hepatic scarring, cirrhosis, or hepatocellular carcinoma (HCC)
- In addition, the claims cover MN-001 for reducing hepatic fibrosis and hepatic scarring in a patient with advanced NASH.
- The claims are for oral administration, including tablets, capsules, and liquid dosage forms, according to MediciNova.
For further details see:
MediciNova to get Canadian patent for liver disease drug MN-001